Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study

Luca Guarnera, Soren Lehmann, Konstanze Döhner, Hartmut Döhner, Uwe Platzbecker, Nigel H. Russell, Richard Dillon, Ian Thomas, Gert Ossenkoppele, Marco Vignetti, Edoardo la Sala, Alfonso Piciocchi, Angela Villaverde Ramiro, Laura Tur, Carmelo Gurnari, Lars Bullinger, Jesús María Hernández-Rivas, Maria Teresa Voso

Blood (2023) 142 (Supplement 1): 727.

https://doi.org/10.1182/blood-2023-185121

Published: 2023

Journal Articles

Inherited Thrombocytopenias Predisposing to Hematologic Neoplasms. Experience of the Spanish Group for Inherited Platelet Disorders (GEAPC)

Blood (2023) 142 (Supplement 1): 1357.

https://doi.org/10.1182/blood-2023-180690

Published: 2023

Journal Articles

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 623.

https://doi.org/10.1182/blood-2023-179160

Published: 2023

Journal Articles

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1461.

https://doi.org/10.1182/blood-2023-186265

Published: 2023

Journal Articles

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1533.

https://doi.org/10.1182/blood-2023-184745

Published: 2023

Journal Articles

Mutually-Exclusive Pathways between IKZF1 plus and RAS Mutations and TP53 double-Hit Alterations Lead Relapse in B-Other, Ph-like and Hyperdiploidy Genetic Groups in Adult B-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1616.

https://doi.org/10.1182/blood-2023-182163

Published: 2023

Journal Articles

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Blood (2023) 142 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2023-186277

Published: 2023

Journal Articles

TRAF3 -Inactivated Chronic Lymphocytic Leukemia Cells Show an Enhanced Metabolic Plasticity That Can be Attenuated By Glutaminolysis and Mitochondrial Pyruvate Import Inhibition

Claudia Perez Carretero, Miguel Quijada Álamo, Mariana Tannoury, Léa Dehgane, Alberto Rodríguez-Sánchez, Teresa González, Maria Rocio Benito Sanchez, Elise Chapiro, Ana E. Rodriguez, Florence Nguyen-Khac, Santos A. Susin, Jesús María Hernández-Rivas

Blood (2023) 142 (Supplement 1): 1889.

https://doi.org/10.1182/blood-2023-187054

Published: 2023

Journal Articles

ZMYM3 Mutations Cooperate with NOTCH1 Alterations, Reduce Histone H4 Acetylation and Promote Apoptosis Evasion in Chronic Lymphocytic Leukemia

Alberto Rodríguez-Sánchez, Miguel Quijada Álamo, Claudia Perez Carretero, Luis Antonio Corchete Sanchez, Angela Villaverde Ramiro, Cristina Miguel-García, Sandra Santos-Mínguez, Julio Davila Valls, Alfonso Garcia de Coca, Julio Olazabal, Maria Rocio Benito Sanchez, Ana E. Rodriguez, Jesús María Hernández-Rivas

Blood (2023) 142 (Supplement 1): 1886.

https://doi.org/10.1182/blood-2023-188550

Published: 2023

Journal Articles

Novel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis

Ana Marín-Quílez, Christian Andrea Di Buduo, Lorena Díaz-Ajenjo, Vittorio Abbonante, Elena Vuelta, Paolo Maria Soprano, Cristina Miguel-García, Sandra Santos-Mínguez, Inmaculada Serramito-Gómez, Pedro Ruiz-Sala, María Jesús Peñarrubia, Emilia Pardal, Jesús María Hernández-Rivas, José Ramón González-Porras, Ignacio García-Tuñón, Rocío Benito, José Rivera, Alessandra Balduini, José María Bastida

Blood (2023) 141 (4): 406–421.

https://doi.org/10.1182/blood.2022016995

Published: 2023

Includes: Supplemental data

Journal Articles

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Blood (2022) 140 (Supplement 1): 551–554.

https://doi.org/10.1182/blood-2022-167480

Published: 2022

Journal Articles

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Blood (2022) 140 (Supplement 1): 6053–6055.

https://doi.org/10.1182/blood-2022-165088

Published: 2022

Journal Articles

Enabling the Implementation of Next-Generation Sequencing into Clinical Diagnosis: Nemhesys Project

Blood (2022) 140 (Supplement 1): 13122–13124.

https://doi.org/10.1182/blood-2022-163285

Published: 2022

Journal Articles

NOTCH1 Signaling Is Dysregulated in CLL By the Deubiquitinase USP28 That Is Recurrently Affected By Del(11q) and Can be Therapeutically Targeted

Alena Sophie Ehrmann, Miguel Quijada Álamo, Viola Close, Min Guo, Claudia Pérez Carretero, Luis A Corchete, Eugen Tausch, Christof Schneider, Hartmut Döhner, Stephan Stilgenbauer, Franz Oswald, Jesus Maria Hernández-Rivas, Daniel Mertens

Blood (2022) 140 (Supplement 1): 4100–4102.

https://doi.org/10.1182/blood-2022-158168

Published: 2022

Journal Articles

Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study

Pilar Martínez Sánchez, Gerhard Zugmaier, Paul Gordon, Elias Jabbour, José J. Rifón Roca, Stefan Schwartz, Erika Borlenghi, Francoise Huguet, Jesús María Hernández-Rivas, Federico Lussana, Céline Berthon, Priti Kadu, Hansen Wong, Ana Markovic, Yuliya Katlinskaya, Alessandro Rambaldi

Blood (2022) 140 (Supplement 1): 6122–6124.

https://doi.org/10.1182/blood-2022-157117

Published: 2022

Journal Articles

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Blood (2022) 140 (Supplement 1): 739–742.

https://doi.org/10.1182/blood-2022-167138

Published: 2022

Journal Articles

Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

Blood (2022) 140 (Supplement 1): 9740–9743.

https://doi.org/10.1182/blood-2022-168599

Published: 2022

Journal Articles

IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Blood (2022) 140 (Supplement 1): 6345–6347.

https://doi.org/10.1182/blood-2022-162159

Published: 2022

Journal Articles

Chemotherapy-Based Regimes Increase Karyotype Complexity of Del(11q) CLL Cells and Impact the Response to Subsequent Ibrutinib Treatment

Miguel Quijada Álamo, Laura Z. Rassenti, Emanuela M. Ghia, Tuan Tran, Monica Spydell, Elsa Molina, Claudia Pérez Carretero, Luis A. Corchete, Teresa González, Jesús María Hernández-Rivas, Thomas J. Kipps

Blood (2022) 140 (Supplement 1): 4113–4114.

https://doi.org/10.1182/blood-2022-166403

Published: 2022

NARROW

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study

Inherited Thrombocytopenias Predisposing to Hematologic Neoplasms. Experience of the Spanish Group for Inherited Platelet Disorders (GEAPC)

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Mutually-Exclusive Pathways between IKZF1 plus and RAS Mutations and TP53 double-Hit Alterations Lead Relapse in B-Other, Ph-like and Hyperdiploidy Genetic Groups in Adult B-Cell Acute Lymphoblastic Leukemia

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

TRAF3 -Inactivated Chronic Lymphocytic Leukemia Cells Show an Enhanced Metabolic Plasticity That Can be Attenuated By Glutaminolysis and Mitochondrial Pyruvate Import Inhibition

ZMYM3 Mutations Cooperate with NOTCH1 Alterations, Reduce Histone H4 Acetylation and Promote Apoptosis Evasion in Chronic Lymphocytic Leukemia

Novel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Enabling the Implementation of Next-Generation Sequencing into Clinical Diagnosis: Nemhesys Project

NOTCH1 Signaling Is Dysregulated in CLL By the Deubiquitinase USP28 That Is Recurrently Affected By Del(11q) and Can be Therapeutically Targeted

Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Chemotherapy-Based Regimes Increase Karyotype Complexity of Del(11q) CLL Cells and Impact the Response to Subsequent Ibrutinib Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only